Tempus AI partners with Boehringer Ingelheim on cancer research

CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a technology company focused on artificial intelligence in healthcare with a market capitalization of $11.93 billion and impressive revenue growth of 43% in the last twelve months, has announced a multi-year strategic collaboration with pharmaceutical giant Boehringer Ingelheim to enhance cancer treatment research and development. According to InvestingPro analysis, the company’s stock has delivered a remarkable 104% return year-to-date, reflecting strong investor confidence in its AI-driven healthcare solutions. This partnership aims to integrate Tempus’s extensive de-identified database and analytical platform with Boehringer Ingelheim’s oncology pipeline.

The collaboration is set to harness molecular, clinical, and imaging data to support the discovery and development of new cancer treatments. By leveraging Tempus’s AI-powered platform, Boehringer Ingelheim intends to deepen its understanding of cancer biology and speed up its drug discovery processes. While Tempus maintains a strong gross profit margin of 57%, InvestingPro data indicates the company operates with moderate debt levels and currently trades above its Fair Value, suggesting investors should carefully monitor its valuation metrics.

Mark Paul Petronczki, Head of Oncology Research at Boehringer Ingelheim, emphasized the potential of combining Tempus’s real-world data with internal pre-clinical experimental data to advance their understanding of the disease. Jan Nygaard Jensen, Head of Computational Innovation at Boehringer Ingelheim, also highlighted the critical role of real-world patient data and AI methodologies in accelerating drug development.

Ryan Fukushima, Chief Operating Officer at Tempus, expressed enthusiasm for the expanded work with Boehringer Ingelheim, stressing both companies’ commitment to leveraging data and AI in research for faster development of novel treatments.

Tempus, known for its AI-enabled precision medicine solutions, maintains one of the world’s largest libraries of multimodal data. Its operating system aims to make this data accessible and useful for personalized patient care and therapeutic development.

The press release also contained forward-looking statements regarding the expected outcomes of the collaboration. However, it noted that such statements involve risks and uncertainties and should not be relied upon as predictions of future events.

This strategic collaboration represents a significant step in the use of AI and real-world data to advance the fight against cancer, potentially leading to breakthroughs in treatment for hard-to-treat cancers. The information is based on a press release statement from Tempus AI, Inc. For investors seeking deeper insights, InvestingPro offers comprehensive analysis through its Pro Research Report, including detailed financial health metrics, 8 additional ProTips, and expert analysis of Tempus’s market position among 1,400+ top US stocks.

In other recent news, Tempus AI Inc. reported a significant 75.4% increase in revenue for the first quarter of 2025, reaching $255.7 million, surpassing the forecast of $248.5 million. The company achieved an earnings per share of -$0.24, which was better than the anticipated -$0.26. Tempus AI also raised its full-year 2025 revenue guidance to $1.25 billion, projecting an 80% year-over-year growth. Additionally, Tempus AI secured a $200 million data and modeling license agreement with AstraZeneca and the Pathos foundation, contributing to a total contract value of over $1 billion. This partnership is expected to drive medium-term growth in the company’s Data and Services business. Morgan Stanley raised its price target for Tempus AI to $65 from $60, maintaining an Overweight rating, due to the company’s strong first-quarter performance and promising developments in minimal residual disease testing. The company’s genomics revenue grew by 89% year-over-year, and oncology testing saw a 31% increase, indicating robust growth across its segments. Despite these positive developments, Tempus AI’s stock faced a decline, reflecting cautious investor sentiment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.